The purpose of this study is to investigate the safety and tolerability of AMG 732 in participants with thyroid eye disease (TED). TED is an autoimmune disease in which the eye muscles and fatty tissue behind the eye become inflamed causing the eyeball to bulge.
The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for patients with type 1 diabetes who have a kidney transplant.
The purpose of this study is to evaluate the efficacy, safety and tolerability of subcutaneous teprotumumab in participants with moderate-to-severe active thyroid eye disease (TED). TED is an autoimmune disease in which the eye muscles and fatty tissue behind the eye become inflamed. This can push the eyes forward (bulging) or cause redness and swelling. Symptoms can range from mild to sight-threatening. Current treatment options for moderate/severe TED are not optimal (lots of side effects), but teprotumumab holds promise and is being tested for treatment of TED in this trial.
The purpose of this study is to compare brown adipose tissue (BAT) activity in women/people diagnosed with endometriosis to similar healthy controls. BAT activity is measured twice in a random order during the early part of the menstrual cycle (follicular phase) and following egg release/ovulation (luteal phase). The study team will investigate whether BAT activity in women with endometriosis differs from healthy control women who are of similar age and body mass index.
The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for type 1 diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar.
The purpose of this study is to evaluate a peer-led mental health support program, REACHOUT, for rural and remote communities in British Columbia. REACHOUT is a mobile app that provides free peer-led mental health support to adults with type 1 diabetes (T1D). The REACHOUT intervention spans over six months and empowers adults with T1D to join as either a peer supporter, who will be trained to provide social and emotional assistance, or as a participant, who will receive invaluable support from empathetic peer supporters.
The purpose of this study is to measure patterns of hepatitis C virus (HCV) reinfection after achieving an undetectable viral load at end of treatment on direct-acting aniviral therapy; to determine the threshold of risk reduction practices that protects against HCV reinfection after achieving an undetectable viral load; and to evaluate the potential impact of successful HCV treatment in terms of health care costs and resource utilization.
The purpose of the study is to learn about the impacts of Cyclic Progesterone and Spironolactone on the menstrual cycles, luteinizing hormone and testosterone levels, and quality of life experiences of women living with polycystic ovary syndrome (PCOS).
Evaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption. In this study investigators propose to enroll at least 20 people who participated in phase 1 and who were determined to have subclinical lipohypertrophy to examine the correlation between glycemic control and amount of insulin injected in subclinical hypertrophic areas using capillary blood glucose and continuous glucose monitoring.
This study is a 12-month study. There are two different groups in the study. Both groups will enter the study after the graduation from 8-hour diabetes education course taught at VGH, St. Paul's, or Richmond Hospital. The first group will receive on-going support from their peers who have diabetes and are trained specifically to help other patients with diabetes. The second group will receive the usual care.
Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface, ocular movement restriction and double vision, and optic nerve compression and loss of vision.
First line medical therapy is oral or intravenous corticosteroids (CS), which several studies have shown results in reduction of soft tissue congestion, but some studies suggesting that ocular restriction or visual loss may still occur in spite of CS therapy.
In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections. Even with insulin injections, blood glucose (sugar) control is imperfect and leads to many health complications and a shortened life span. This is a pilot clinical trial to test the safety of a drug, ustekinumab, in 20 adult subjects with recent-onset T1D.
The purpose of this study is to learn about the questions people with spinal cord injuries/disorders (SCI/D) and health care professionals have about perimenopause and menopause. This study will help determine the priority areas for research, care and education for persons with SCI/D during perimenopause and menopause. The new knowledge obtained from this study will be used in the translation efforts in perimenopause and menopause care for people with SCI/D.
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.
The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.
The rates of sedentary activity are increasing. Studies have shown that time spent on doing sedentary activities is an independent risk factor for cardiovascular disease. Prior studies have shown that interrupting inactivity improved the body's handling of blood glucose and gene expression. The investigators plan to explore this further by examining the effects of interrupting 4 hours of inactivity with 2 minutes of moderate intensity exercise every 20 minutes on the following metabolic parameters: blood pressure, cortisol, C-Reactive Protein, glucose and insulin levels.